US News

U.S. Medicare plans to cover Biogen Alzheimer’s drug only for trial patients

Published by
Reuters

By Deena Beasley (Reuters) -The U.S. government Medicare program on Tuesday said it plans to cover Alzheimer’s treatments including Biogen Inc’s Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access. Biogen shares were down 7.3% at $224 in extended trading on Tuesday. The decision from the U.S. Centers for Medicare and Medicaid Services (CMS), the health agency that runs Medicare, could change as it seeks comment from companies and patients. A final decision is due on April 11. The unusual move to require clinical trials for recipients of the already…

Read More

Facebook Comments

Check Also

States Investigating Surge In Mortality Rate Among 18–49-Year-Olds, Majority Unrelated To COVID-19

States Investigating Surge In Mortality Rate Among 18–49-Year-Olds, ...

Archives